

## Hamilton Laboratories

[View the current Hamilton Laboratories Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/23807-Hamilton+Laboratories.html)

(<http://www.bioportfolio.com/biocorporate/23807-Hamilton+Laboratories.html>)

### Contact Details:

**217 Flinders Street**  
**Adelaide**  
**South Australia**  
**5000**  
**Australia**

Tel: 61 8 82232957  
Fax: 61 8 82321480  
Email: [enquiry@hamiltonlabs.com.au](mailto:enquiry@hamiltonlabs.com.au)

Hamilton Laboratories was founded in September, 1987 by Nicole Ashley Hamilton in Wayland, Massachusetts. We are presently located in Redmond, Washington, a suburb of Seattle. Our first and, still, our main product, is Hamilton C shell, a tools package that recreates the original UNIX C shell and utilities, offering numerous enhancements. Most of our customers are professional software developers at virtually every major software development shop world-wide. Within this segment, Hamilton C shell is used both as a personal productivity tool and as a scripting engine, often in the automation of mission-critical activities such as the build or QA of their own products. Our other major customer segment is within the CAD/CAM industry, where many of our customers use Hamilton C shell for tasks such as reading or writing TAR-format tapes used to exchange part drawing files with a UNIX workstation.

From 1995 through 2001, we also offered on-site training, but that's been discontinued, along with any consulting services, to focus on the product business

### Recent Publications by Hamilton Laboratories:



- [Cholesterol-depleting statin drugs protect postmitotically differentiated human neurons against ethanol- and human immunodeficiency virus type 1-induced oxidative stress in vitro.](#)  
*The majority of human immunodeficiency virus type 1 (HIV-1)-infected...* 7th July, 2007  
Dorrance H. Hamilton Laboratories, Division of Infectious Diseases, - J Virol. 2007 Feb;81(3):1492-501. Epub 2006 Nov 15. ([DOI Direct Link](#))
- [HIV-1 Vpr potently induces programmed cell death in the CNS in vivo.](#)  
*The human immunodeficiency virus type 1 (HIV-1) accessory protein Vpr has...* 6th April, 2007  
The Dorrance H. Hamilton Laboratories, Division of Infectious Diseases and- DNA Cell Biol. 2007 Feb;26(2):116-31. ([DOI Direct Link](#))
- [siRNA targeting vaccinia virus double-stranded RNA binding protein \[E3L\] exerts potent antiviral effects.](#)

- The Vaccinia virus gene, E3L, encodes a double-stranded RNA...* 1st July, 2006  
The Dorrance H. Hamilton Laboratories, Division of Infectious Diseases,- Virology. 2006 May 10;348(2):489-97. Epub 2006 Feb 9. ([DOI Direct Link](#))
- [Molecular interactions of human immunodeficiency virus type 1 with primary human oral keratinocytes.](#)  
*Infection of the oral mucosa of human immunodeficiency virus type 1...* 20th August, 2005  
The Dorrance H. Hamilton Laboratories, Center for Human Virology and- J Virol. 2005 Jul;79(13):8440-53. ([DOI Direct Link](#))
  - [Down-modulation of the CXCR4 co-receptor by intracellular expression of a single chain variable fragment \(SFv\) inhibits HIV-1 entry into primary human brain microvascular endothelial cells and post-mitotic neurons.](#)  
*Our laboratories previously demonstrated that expression of a single chain...* 26th July, 2005  
The Dorrance H. Hamilton Laboratories, Center for Human Virology and- Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):48-57. ([DOI Direct Link](#))
  - [The RNA helicase DDX1 is involved in restricted HIV-1 Rev function in human astrocytes.](#)  
*Productive infection by human immunodeficiency virus type 1 (HIV-1) in the...* 21st July, 2005  
The Dorrance H. Hamilton Laboratories, Center for Human Virology and- Virology. 2005 Jun 5;336(2):299-307. ([DOI Direct Link](#))
  - [Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines.](#)  
*Human immunodeficiency virus type 1 (HIV-1) DNA integration is an...* 9th June, 2005  
The Dorrance H. Hamilton Laboratories, Center for Human Virology and- Virology. 2005 May 10;335(2):177-84. ([DOI Direct Link](#))
  - [The perlecan heparan sulfate proteoglycan mediates cellular uptake of HIV-1 Tat through a pathway responsible for biological activity.](#)  
*Cell surface heparan sulfate proteoglycans (HSPGs) mediate internalization...* 12th January, 2005  
The Dorrance H. Hamilton Laboratories, Division of Infectious Diseases and- Virology. 2004 Dec 20;330(2):481-6. ([DOI Direct Link](#))
  - [A DEAD box protein facilitates HIV-1 replication as a cellular co-factor of Rev.](#)  
*HIV-1 Rev escorts unspliced viral mRNAs out of the nucleus of infected...* 12th January, 2005  
Division of Infectious Diseases and Environmental Medicine, Department of- Virology. 2004 Dec 20;330(2):471-80. ([DOI Direct Link](#))
  - [Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains.](#)  
*RNA interference, a natural biological phenomenon mediated by small...* 24th December, 2004  
Dorrance H. Hamilton Laboratories, Center for Human Virology and- J Virol. 2004 Dec;78(24):13687-96. ([DOI Direct Link](#))
  - [HIV-1 Vif versus APOBEC3G: newly appreciated warriors in the ancient battle between virus and host.](#)  
*The ability of the nonlentiviral retrovirus spleen necrosis virus (SNV) to...* 28th July, 2004  
Hamilton Laboratories, Center for Human Virology and Biodefense, Division- Trends Microbiol. 2004 Apr;12(4):145-8.
  - [Cross-packaging of human immunodeficiency virus type 1 vector RNA by spleen necrosis virus proteins: construction of a new generation of spleen necrosis virus-derived retroviral vectors.](#)  
*The ability of the nonlentiviral retrovirus spleen necrosis virus (SNV) to...* 30th June, 2004  
Dorrance H. Hamilton Laboratories, Center for Human Virology and- J Virol. 2004 Jun;78(12):6480-8. ([DOI Direct Link](#))
  - [HIV-1-mediated apoptosis of neuronal cells: Proximal molecular mechanisms of HIV-1-induced encephalopathy.](#)  
*The induction of neuronal cell death in vivo has been recognized as a...* 23rd June, 2004  
Dorrance H. Hamilton Laboratories, Center for Human Virology and- Proc Natl Acad Sci U S A. 2004 May 4;101(18):7070-5. Epub 2004 Apr 21. ([DOI Direct Link](#))
  - [Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.](#)  
*The failure to develop vaccines to protect against important infectious...* 29th April, 2004  
The Dorrance H. Hamilton Laboratories, Center for Human Virology,- Curr HIV Res. 2003 Apr;1(2):229-37.

- [Reduction of serum melatonin levels in HIV-1-infected individuals' parallel disease progression: correlation with serum interleukin-12 levels.](#)  
*BACKGROUND: During the natural history of human immunodeficiency virus...*13th February, 2004  
 The Dorrance H. Hamilton Laboratories, Center for Human Virology, Division- Infection. 2003  
 Dec;31(6):379-82. ([DOI Direct Link](#))

**Press Releases on Hamilton Laboratories:**

<a href="#">h1n1 Pandemic Preparedness: Strengthening International Collaboration</a>	6th November, 2009	Meridian International Center	WASHINGTON, Nov. 6 <i>/PRNewswire-USNewswire/ -- Meridian International Center will convene government leaders, diplomats, policymakers, scientists, and public health officials in two roundtable</i>
<a href="#">Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution</a>	6th November, 2009	Caraco Pharmaceutical Laboratories, Ltd.	DETROIT, Nov. 6 <i>/PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US</i>
<a href="#">Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution</a>	6th November, 2009	Caraco Pharmaceutical Laboratories, Ltd.	DETROIT, Nov. 6 <i>/PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from the US</i>
<a href="#">Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant</a>	6th November, 2009	Boston Scientific Corporation	Q3 2009 Results -----
<a href="#">DUSA Pharmaceuticals Reports Third Quarter 2009 Corporate Highlights and Financial Results</a>	6th November, 2009	DUSA Pharmaceuticals, Inc.	-- Non-GAAP loss for the third quarter of 2009 improved 86% year over year, and narrowed to \$0.2 million. Management Comments: "We are excited to report the improvement in many

**BioNews Results for Hamilton Laboratories**



- [Targacept Unveils Stellar Depression Drug Data: BioBuzz](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

